Isoray, Inc. was a medical technology company dedicated to the development, manufacturing, and commercialization of Cesium-131 (Cs-131) brachytherapy seeds. These seeds are a type of internal radiation therapy used to treat various forms of cancer, with a significant focus on prostate cancer. Isoray's mission was to provide a highly targeted, effective, and minimally invasive treatment option for cancer patients, aiming to improve outcomes and quality of life. Beyond prostate cancer, the company actively explored and supported the use of its Cs-131 seeds for other cancers, including brain, lung, head and neck, gynecological, and colorectal cancers. Isoray was known for its proprietary isotope purification and seed manufacturing processes. In March 2023, Isoray completed a merger with Viewpoint Molecular Targeting, Inc., and the combined company was renamed Perspective Therapeutics, Inc. (NYSE: CATX). This strategic combination aimed to leverage Isoray's isotope expertise with Viewpoint's pipeline of targeted alpha-particle therapies.
The Richland facility served as Isoray's corporate headquarters, primary manufacturing site for Cesium-131 brachytherapy seeds, and center for research and development activities.
The headquarters housed specialized laboratories, cleanroom environments, and manufacturing equipment essential for the production of medical isotopes and brachytherapy seeds, adhering to strict regulatory standards.
Isoray's work culture likely fostered innovation, precision, and a strong commitment to patient care. As a company in the medical device and oncology field, collaboration among scientific, engineering, and commercial teams would have been crucial.
This location was vital as it was the core of Isoray's production capabilities, enabling the company to supply its unique Cesium-131 seeds to medical facilities. Its presence in Richland, a city with a history in nuclear science, may have offered strategic advantages.
Isoray's primary market for its Cesium-131 brachytherapy products was the United States. While the company may have engaged in limited international sales or sought partnerships for broader distribution, its main commercial activities, regulatory approvals, and patient treatments were concentrated in the U.S. healthcare system prior to its merger.
350 Hills Street, Suite 106
Richland
WA
USA
Address: N/A
N/A
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Isoray' leadership includes:
Isoray has been backed by several prominent investors over the years, including:
In the 12 months leading up to its merger with Viewpoint Molecular Targeting (completed March 2023), Isoray's executive team primarily saw transitions related to the merger. Key Isoray leadership roles concluded as the new entity, Perspective Therapeutics, formed its leadership. There were no new executive hires to Isoray's distinct leadership team during this period.
Discover the tools Isoray uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Based on common corporate practices and patterns observed in similar companies, Isoray likely used email formats such as [first_initial][last]@isoray.com or [first].[last]@isoray.com. These are standard conventions for professional communication.
flast@isoray.com (e.g., jdoe@isoray.com) and first.last@isoray.com (e.g. jane.doe@isoray.com)
Format
lwoods@isoray.com
Example
70%
Success rate
GlobeNewswire • March 1, 2023
Isoray, Inc. and Viewpoint Molecular Targeting, Inc. announced the successful completion of their previously announced merger agreement. The combined company was renamed Perspective Therapeutics, Inc. and began trading on the NYSE American under the ticker symbol 'CATX'. The merger aimed to create a leader in targeted alpha-particle therapies for cancer....more
GlobeNewswire • August 2, 2021
Isoray, Inc. announced that the first pediatric patients were treated using its proprietary Cesium-131 isotope in a novel approach to Total Body Irradiation (TBI) for conditioning prior to bone marrow transplant for high-risk leukemia. This marked a significant step in exploring new applications for Cesium-131....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Isoray, are just a search away.